Malesci A, De Fazio C, Festorazzi S, Bonato C, Valentini A, Tacconi M, Bekkering M, Giacovelli G, D'Amato M, Rovati L C
Istituto di Medicina Interna, Università di Milano, Italy.
Arzneimittelforschung. 1992 Nov;42(11):1359-62.
The effect of two different single oral doses of loxiglumide (CR 1505, CAS 107097-80-3) on gall-bladder emptying induced by a 550-cal standard mixed meal in 6 healthy volunteers was studied. Following placebo, the maximal gall-bladder emptying occurred about 90 min after the meal (minimal residual gall-bladder volume 27.4% of basal volume). Loxiglumide 400 or 800 mg dose-dependently inhibited the physiologica gall-bladder emptying. Loxiglumide plasma levels dose-dependently increased. The inhibition of gall-bladder emptying and the kinetic of loxiglumide plasma levels were temporally related. The results of the present study confirm that oral loxiglumide is a potent orally active cholecystokinin (CCK) antagonist in man and that CCK is the major physiological mediator of gallbladder emptying in response to meal.
研究了两种不同单次口服剂量的洛西格列胺(CR 1505,化学物质登记号107097 - 80 - 3)对6名健康志愿者进食550卡路里标准混合餐后胆囊排空的影响。服用安慰剂后,最大胆囊排空发生在餐后约90分钟(胆囊最小残余体积为基础体积的27.4%)。400或800毫克的洛西格列胺剂量依赖性地抑制生理性胆囊排空。洛西格列胺的血浆水平呈剂量依赖性升高。胆囊排空的抑制与洛西格列胺血浆水平的动力学在时间上相关。本研究结果证实,口服洛西格列胺是一种对人体有效的口服活性胆囊收缩素(CCK)拮抗剂,并且CCK是进食后胆囊排空的主要生理介质。